Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$7.76 USD
-0.18 (-2.27%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.76 0.00 (0.00%) 6:22 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
Vir Biotechnology, Inc. [VIR]
Reports for Purchase
Showing records 21 - 40 ( 53 total )
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Data Updates on Programs Targeting HBV, Influenza, and COVID-19 Poised to Turn 2023 Into a Pivotal Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; XEVUDY Path Forward Focused on Ex-U.S. Markets; Broad Infectious Disease Pipeline Progressing
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Brii Opts in to VIR-3434, Providing Another Path to a Potential $50B-Plus HBV Cure Market in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Amid COVID-19 Uncertainty, Robust Capital Position Should Enable Value Realization of Pipeline; Lowering PT to $125
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Emerging HBV Program With Best-in-Class Traits Should Offset Potential Shortfall in COVID-19 Franchise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Potential Multi-Blockbuster Chronic HBV Program Further Validated at APASL 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Although Higher Sotrovimab Dose May Maintain Activity Against SARS-CoV-2, FDA Amends EUA; PT to $200; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Sotrovimab Continues to Shine on the COVID-19 Stage; HBV, HIV, Flu Programs on Track With 2022 Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Upping Near-Term Revenue Estimates on Robust Sotrovimab Uptake; Broad Pipeline on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
And Then There Was One; Potent Antiviral Sotrovimab to Soften Global Omicron Crisis; Upping PT to $300; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Sotrovimab Leads Race to Treat High-Risk SARS-CoV-2 Patients With Positive Preclinical Omicron Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Well-Positioned for Robust Prophylaxis and Post-Infection COVID-19 Antiviral Market; Upping PT to $200; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Confirms 660,000 Doses of Sotrovimab Have Been Reserved, Implying Potential Blockbuster COVID-19 Revenues
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Broad Antiviral Pipeline Progressing; Sotrovimab Well-Positioned Amid Spike in COVID-19 Cases
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Positive HBV Program Updates From EASL; Additional Data Updates Expected 2H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Sotrovimab''s Robust Efficacy in Early Disease COVID-19 Confirmed; NIH Guidelines Reflect Differentiation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Sotrovimab EUA Validates Vir''s Antiviral Platform, Sets Stage for Global Rollout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Vir Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Sotrovimab EUA Validates Vir''s Antiviral Platform, Sets Stage for Global Rollout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P